Actavis PLC (ACT): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Actavis ( ACT) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.3%. By the end of trading, Actavis rose $9.81 (4.7%) to $220.37 on heavy volume. Throughout the day, 5,670,722 shares of Actavis exchanged hands as compared to its average daily volume of 1,636,700 shares. The stock ranged in a price between $210.49-$222.24 after having opened the day at $211.45 as compared to the previous trading day's close of $210.56. Other companies within the Health Care sector that increased today were: Ultragenyx Pharmaceutical ( RARE), up 17.1%, Raptor Pharmaceutical ( RPTP), up 14.9%, Biolase ( BIOL), up 12.4% and China Biologic Products ( CBPO), up 11.9%.

Actavis plc, an integrated specialty pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally. Actavis has a market cap of $35.1 billion and is part of the drugs industry. Shares are up 25.3% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Actavis a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity.

On the negative front, Onconova Therapeutics ( ONTX), down 36.6%, Cryolife ( CRY), down 12.6%, Aoxing Pharmaceutical Company ( AXN), down 11.5% and Cardiome Pharma Corporation ( CRME), down 9.7%.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Alphabet, Caterpillar, Coca-Cola and Amazon - 5 Things You Must Know

Alphabet, Caterpillar, Coca-Cola and Amazon - 5 Things You Must Know

Alphabet's Earnings Beat and 4 Other Business Stories You Must Know Tuesday

Alphabet's Earnings Beat and 4 Other Business Stories You Must Know Tuesday

Alphabet Shares Gain as Investors Shrug Off Q1 Google Spending Spree

Alphabet Shares Gain as Investors Shrug Off Q1 Google Spending Spree

SAP Shares Leap After Cloud Business Prompts Full-Year Profit Guidance Hike

SAP Shares Leap After Cloud Business Prompts Full-Year Profit Guidance Hike

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns